GLP-1 competition: Semaglutide surpasses dulaglutide this year

On November 3, 2021, Novo Nordisk released its financial report for the third quarter of 2021. Operating income was US$5.895 billion, a year-on-year increase of 15%, of which revenue in China was RMB 4.1 billion, a year-on-year increase of 11%.

The effect of semaglutide is better than that of dulaglutide, and it still maintains a high growth rate.

The effect of semaglutide is better than that of dulaglutide, and it still maintains a high growth rate.

In the first three quarters, sales of injectable semaglutide Ozempic was US$3.805 billion, oral semaglutide Rybelsus had sales of US$499 million in the first three quarters, and weight loss drugs Saxenda (liraglutide) and Wegovy (semaglutide) The total sales in the first three quarters were US$983 million. The total sales of Semaglutide in the first three quarters should be about US$4.6 billion. Eli Lilly’s Trulicity’s sales in the first three quarters were US$4.588 billion. There is no suspense for Semaglutide to fully surpass dulaglutide this year.

In the US market, the number of new prescriptions for semaglutide has far exceeded that of dulaglycotide.

In the weight-loss drug market, liraglutide needs to be injected once a day. Previously, its annual sales had stabilized at around US$800 million. Semaglutide (Wegovy) only needs to be injected once a week, and the volume will be increased quickly after it goes on the market. The total sales this year will exceed 1.3 billion US dollars.